 |
 |
 |
| |
De: PR Newswire
Brasil
Para: THERESA CATHARINA DE GÓES CAMPOS
Assunto: TAXUS(R) Liberte(TM) Stent System
Receives European Approval for Three Complex
Coronary Procedures
TAXUS(R) Liberte(TM) Stent System Receives
European Approval for Three Complex Coronary
Procedures
16 de maio de 2006 09:00 HORALOCAL
TAXUS(R) Liberte(TM) Stent System Receives
European Approval for
Three Complex Coronary Procedures
Boston Scientific's Second-Generation Stent
System Now Approved for
Treatment of Acute Mycocardial Infarction, Total
Occlusions and
In-Stent Restenosis
Large Vessel TAXUS Liberte Stent Also Receives
CE Mark
NATICK, Mass., and PARIS, May 16 /PRNewswire/ --
Boston Scientific
Corporation (NYSE: BSX) announced today that it
has received
indication extensions to the European CE mark
for its TAXUS(R)
Liberte(TM) paclitaxel-eluting coronary stent
system for use in some
of the most challenging coronary procedures.
The new labeling reflects a review of TAXUS
clinical data by the
European regulatory agency. In addition to its
existing indication
for the treatment of de-novo lesions in native
coronary arteries, the
TAXUS Liberte stent system is now indicated in
Europe for the
treatment of restenotic lesions (in-stent
restenosis, or ISR) and
total occlusions (TO) in patients with coronary
artery disease,
including acute myocardial infarction (AMI).
These three new
indications account for more than 20 percent of
all coronary
interventions.
The TAXUS Liberte stent system is now the only
drug-eluting stent
system with these new indications for use in
Europe.
This revised labeling follows the excellent
clinical outcomes the
TAXUS stent system has shown in the treatment of
complex lesions in
recent clinical trials and registries, including
the TAXUS V ISR
trial and the MILESTONE II, WISDOM, ARRIVE, and
OLYMPIA registries.
In addition to the three new indications, the
large vessel diameter
TAXUS Liberte stent also received the CE mark.
This stent uses a
modified cell design intended for drug delivery
in larger vessels,
and will be available in a 4.0 mm diameter and
seven different
lengths.
"The European approval for new indications
recognizes the
strong long-term performance of the TAXUS stent
system across complex
patients and lesions," said Jeff Goodman,
President of Boston
Scientific International. "It allows physicians
to treat difficult
cases of coronary artery disease with the most
advanced technology."
Boston Scientific is a worldwide developer,
manufacturer and marketer
of medical devices whose products are used in a
broad range of
interventional medical specialties. For more
information, please
visit: www.bostonscientific.com.
This press release contains forward-looking
statements. Boston
Scientific wishes to caution the reader of this
press release that
actual results may differ from those discussed
in the forward-looking
statements and may be adversely affected by,
among other things,
risks associated with new product development
and commercialization,
clinical trials, intellectual property,
regulatory approvals,
competitive offerings, integration of acquired
companies, Boston
Scientific's overall business strategy, and
other factors described
in Boston Scientific's filings with the
Securities and Exchange
Commission.
SOURCE Boston Scientific Corporation
05/16/2006
CONTACT: Geraldine Varoqui, Boston Scientific PR
Manager
International, Tel: +49-2102-489-461, varoquig@bsci.com;
or Maren
Koban, BSC press office, Tel: +44-20-7973-4497,
mkoban@hillandknowlton.com
Web site: http://www.bostonscientific.com
(BSX)
BNED: NG
FONTE: PR NEWSWIRE LATIN AMERICA
CORAL GABLES - MIAMI-US
CONTATOS: USA-MARY D'LEON
BRASIL-NÉLIA GARCIA
TELS: USA:1-305-507-2550/BRASIL:55-21-2132-8461
FAXES: USA:1-305-461-8670/BRASIL:55-21-2132-8469
E-MAILS: nelia_garcia@prnewswire.com.br
mary_dleon@prnewswire.com
PALAVRA-CHAVE: RJ
PALAVRA-CHAVE/RAMO DE ATIVIDADE: MEDICINA
PALAVRA-CHAVE/EMPRESA: BOSTON SCIENTIFIC
CORPORATION
O texto acima, distribuído pela PR Newswire
Brasil, é de inteira responsabilidade de seu
cliente. A utilização deste material não implica
em custo.
|
|
|
|
